Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of meetings, deadlines, and what-not has, predictably, returned. To cope, we are resorting, as always, to cups of stimulation. And all the better to help us tune out a long-running windstorm attacking the Pharmalot campus and nearby environs. The ongoing, 60-mile-per-hour gusts give new meaning to the idea that life is a breeze. Meanwhile, here are some tidbits. Hope your day goes well and do stay in touch.
Roche (RHHBY) is buying Spark Therapeutics (ONCE) for $4.8 billion in hopes of expanding its presence in the market for treating hemophilia, The Wall Street Journal reports. Hemophilia is a new and emerging category for Roche; in 2017, the Food and Drug Administration approved a hemophilia A treatment, Hemlibra, which analysts expect will have billions of dollars in yearly sales. Moreover, as STAT notes, the deal underscores the desire among the largest drug makers to sell gene therapies and that such big biopharma deals are back.